Correlation analysis of serum CCL3, TRACP-5b and Sclerostin with the prognosis of multiple myeloma patients
Serum CCL3, TRACP-5b and Sclerostin in multiple myeloma patients
Abstract
[Objective] To investigate the clinical use of Sclerostin, tartrate-resistant acid phosphatase 5b (TRACP-5b), and serum C-C motif chemokine ligand 3 (CCL3) levels in assessing the health and prognosis of patients with multiple myeloma.
[Methods] 250 patients with multiple myeloma who visited the hospital between January 2023 and December 2024 were selected as the observation group, whereas 150 healthy individuals who were evaluated there during that time made up the control group. The levels of serum CCL3, TRACP-5b and Sclerostin in the observation group before and after treatment were compared, as were the levels of serum CCL3, TRACP-5b and Sclerostin. The levels of serum CCL3, TRACP-5b and Sclerostin in MM patients with different tumor stages and different degrees of bone destruction were compared, and the univariate and multivariate factors of death within one year in MM patients were analyzed. To compare the predictive efficacy of single and combined detection of serum CCL3, TRACP-5b and Sclerostin for death within one year in patients with multiple myeloma.
[Results] The levels of serum CCL3, TRACP-5b and Sclerostin in the observation group before and after treatment were significantly greater than those in the control group, and the differences were statistically significant (P<0.05). After treatment, the levels of serum CCL3, TRACP-5b and Sclerostin in the observation group were significantly lower than those before treatment, and the differences were statistically significant (P<0.05). There were statistically significant differences in tumor stage, classification of degree of bone destruction, CCL3 level, TRACP-5b level and Sclerostin level (P<0.05). Multivariate analysis revealed that tumor stage, the degree of bone destruction, the CCL3level, the TRACP-5b level and the Sclerostin level were the factors influencing death within one year in patients with multiple myeloma (P<0.05). The levels of serum CCL3, TRACP-5b and Sclerostin have relatively high predictive efficacy for death within one year in patients with multiple myeloma. The sensitivity of the combined detection of the three indicators was 90.3%, the specificity was 87.4%, and the area under the receiver operating characteristic curve (AUC) was 0.937, which was significantly greater than that of CCL3 (Z=3.061, P=0.002), TRACP-5b (Z=3.625, P<0.001), and Sclerostin (Z=2.579). When tested separately (P =0.010), there was no statistically significant difference in the AUC among the three indicators (P>0.05).
[Conclusion] CCL3, TRACP-5b and Sclerostin are involved in the occurrence and development of multiple myeloma and have high value in predicting death within one year.
References
2.Tavakoli Pirzaman A, Ebrahimi P, Hasanpour AH, Shakeri M, Babajani B, Pourali Ganji Z, Babaei H, Rahmati A, Hosseinzadeh R, Doostmohamadian S, Kazemi S. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231202391. doi: 10.1177/15330338231202391. PMID: 37728167; PMCID: PMC10515583.
3.Sun C, Zhang W, Liu H, Ding Y, Guo J, Xiong S, Zhai Z, Hu W. Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification. Sci Rep. 2024 Jul 2;14(1):15142. doi: 10.1038/s41598-024-65937-x. PMID: 38956267; PMCID: PMC11219856.
4.Thakral B, Vijayanarayanan A, Medeiros LJ, Lin P. Cytogenetic and molecular aberrations at diagnosis and in prognosis of multiple myeloma. Semin Diagn Pathol. 2025 Jul;42(4):150915. doi: 10.1016/j.semdp.2025.150915. Epub 2025 May 17. PMID: 40411938.
5.Seegmiller AC. Flow cytometry in the diagnosis and prognosis of multiple myeloma. Semin Diagn Pathol. 2025 Sep;42(5):150942. doi: 10.1016/j.semdp.2025.150942. Epub 2025 Jul 25. PMID: 40743872.
6.Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P, Testoni N, Nanni C, Zamagni E, Cavo M, Terragna C. High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis. Blood Cancer J. 2024 Nov 28;14(1):208. doi: 10.1038/s41408-024-01185-6. PMID: 39609411; PMCID: PMC11605000.
7.Martínez-Cordero H, Peña C, Schutz NP, Bove V, Villano F, Beltran C, Donoso J, López-Vidal H, Roa Salinas MA, Soto P, Ochoa P, Duarte P, Remaggi G, Corzo A, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga LD, Fantl D, Ramirez J, Ospina-Idárraga A, Idrobo H, Quintero G, Gomez R, Cantú-Martínez O, Gomez-Almaguer D, Ruiz-Arguelles GJ, Galvez-Cárdenas KM, Salazar LA, Novoa-Caicedo I, Fuentes-Lacouture MC, Spirko P, Arbeláez MI, Pereira M, Valdes J, Vasquez J, von Glasenapp A, Riva E; GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple). Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America. JCO Glob Oncol. 2023 Sep;9:e2300182. doi: 10.1200/GO.23.00182. PMID: 38060975; PMCID: PMC10723854.
8.Liang D, Li X, Bai S, Wang Q, Zeng M, Feng D, Lu B, Li X, Sun Z, Li J, Zhou H, Zhang J, Chen X, Xia Z, Liang Y, Wang H. Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study. Cancer Med. 2024 Oct;13(20):e70270. doi: 10.1002/cam4.70270. Erratum in: Cancer Med. 2024 Nov;13(21):e70406. doi: 10.1002/cam4.70406. PMID: 39422477; PMCID: PMC11487677.
9.Shen N, Zhang J, Xia Y, Shen XX, Wang J, Jin YY, Zhang R, Li JY, Chen LJ. [Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations]. Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):989-994. Chinese. doi: 10.3760/cma.j.issn.0253-2727.2023.12.004. PMID: 38503521; PMCID: PMC10834875.
10.Yu K, Li J, Chen D, Huan W. The Correlation of miR-671-5p with Diagnosis and Prognosis in Multiple Myeloma. Clin Lab. 2023 Aug 1;69(8). doi: 10.7754/Clin.Lab.2023.220826. PMID: 37560870.
11.Solmaz S, Uzun O, Sevindik OG, Demirkan F, Ozcan MA, Ozsan GH, Alacacıoglu I. The effect of hemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. Int J Lab Hematol. 2023 Feb;45(1):13-19. doi: 10.1111/ijlh.13958. Epub 2022 Sep 2. PMID: 36053932.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13.Liao Y, Liu J, Wei M, Chen R, Huang C. Analysis of Correlation between Blood Inflammation Indicators in Peripheral Blood and Prognosis of Patients with Multiple Myeloma. Clin Lab. 2024 Oct 1;70(10). doi: 10.7754/Clin.Lab.2024.240148. PMID: 39382935.
14.Tang S, Long X, Li F, Jiang S, Fu Y, Liu J. Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes. Hematology. 2025 Dec;30(1):2467499. doi: 10.1080/16078454.2025.2467499. Epub 2025 Feb 21. PMID: 39985176.
15.Li JR, Parthasarathy AK, Kannappan AS, Arsang-Jang S, Dong J, Cheng C. Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma. Oncologist. 2024 Nov 4;29(11):e1552-e1564. doi: 10.1093/oncolo/oyae244. PMID: 39250742; PMCID: PMC11639189.
16.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
17.Bao L, Wang YT, Lu MQ, Chu B, Shi L, Gao S, Fang LJ, Xiang QQ, Ding YH, Liu X, Zhao X, Wang MZ, Chen Y, Hu WK. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis. Front Endocrinol (Lausanne). 2023 Apr 27;14:1157969. doi: 10.3389/fendo.2023.1157969. PMID: 37181039; PMCID: PMC10173308.
18.Zhong H, Huang D, Wu J, Chen X, Chen Y, Huang C. 18F FDG PET/CT based radiomics features improve prediction of prognosis: multiple machine learning algorithms and multimodality applications for multiple myeloma. BMC Med Imaging. 2023 Jun 27;23(1):87. doi: 10.1186/s12880-023-01033-2. PMID: 37370013; PMCID: PMC10303834.
19.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
20.Zhang Y, Pan J, Kang H, Peng S, Tung TH, Shen B. Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review. Ann Med. 2024 Dec;56(1):2380301. doi: 10.1080/07853890.2024.2380301. Epub 2024 Jul 22. PMID: 39034813; PMCID: PMC11265304.
21.Jiang JY, Yao FY, Liu J, Wang XL, Huang B, Zhong FM, Wang XZ. A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241232554. doi: 10.1177/15330338241232554. PMID: 38361483; PMCID: PMC10874153.
22.Wang JH, Xiang P, Zhao EJ, Liu LN, Liu YZ, Liang LJ, Cui YS, Fang BJ. Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma. World J Surg Oncol. 2025 Aug 30;23(1):330. doi: 10.1186/s12957-025-03982-0. PMID: 40886007; PMCID: PMC12398977.
23.Zhang YQ, Zhao JS, Wei XF, Feng YF, Fu Y, Chen QL, Zhang QK. [Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Apr;33(2):437-441. Chinese. doi: 10.19746/j.cnki.issn.1009-2137.2025.02.018. PMID: 40326115.
24.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
25.Oğuzman H, Kaçmaz M. The role of pentraxin 3 and oxidative status in the prognosis of multiple myeloma. J Investig Med. 2024 Apr;72(4):333-340. doi: 10.1177/10815589241235662. Epub 2024 Mar 13. PMID: 38373952.
26.Qiao X, Song Z, Geng L, Xing L, Wang Y. Investigating the role of tumor cell heterogeneity and angiogenesis genes in the prognosis of multiple myeloma. Front Immunol. 2025 Jun 25;16:1610833. doi: 10.3389/fimmu.2025.1610833. PMID: 40636123; PMCID: PMC12238041.
27.Ji J, Guo R, Ma J, Cui Y, Li Y, Sun Z, Li J, Fan L, Qu X. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation. Clin Chim Acta. 2023 Aug 1;548:117497. doi: 10.1016/j.cca.2023.117497. Epub 2023 Jul 20. PMID: 37479009.
28.Yan H, Ding Y, Dai W, Wang H, Qin H, Zhai Z, Tao Q. Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma. Clin Exp Med. 2025 May 9;25(1):147. doi: 10.1007/s10238-025-01692-1. PMID: 40346405; PMCID: PMC12064474.
29.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
30.Lei A, Liao X, Zhu P, Xiong M. The significance of autologous hematopoietic stem cell transplantation on immunoglobulin reconstitution and prognosis in elderly patients with multiple myeloma. Hematology. 2023 Dec;28(1):2255800. doi: 10.1080/16078454.2023.2255800. Epub 2023 Sep 21. PMID: 37732626.
31.Xu Y, Cao X, Zhou H, Xu H, Chen B, Bai H. Identifying potential prognosis markers in relapsed multiple myeloma via integrated bioinformatics analysis and biological experiments. Curr Res Transl Med. 2025 Apr-Jun;73(2):103495. doi: 10.1016/j.retram.2025.103495. Epub 2025 Jan 12. PMID: 39818172.
32.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
33.You H, Yao W, Yan L, Zhai Y, Yan Z, Shang J, Yan S, Shi X, Jin S, Ge X, Shen H, Pan J, Wu D, Fu C. Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone. Br J Hematol. 2025 Sep;207(3):869-880. doi: 10.1111/bjh.70015. Epub 2025 Aug 17. PMID: 40824203; PMCID: PMC12436220.
34.Wang F, Shen C. Impact of liquid‒liquid phase separation- and immune-related gene signatures on multiple myeloma prognosis: focus on DDX21 and EZH2. Hematology. 2025 Dec;30(1):2445403. doi: 10.1080/16078454.2024.2445403. Epub 2024 Dec 23. PMID: 39713879.
Copyright (c) 2025 Cuimei Jiang, ManMan Sun, Dashan Gao, Xiaoli Zhang, Jianan Pan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.